Drugs / mRNA-1468
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05701800 | Jan 2023 → Jun 2026 overdue | herpes zoster | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-27 | ModernaTX, Inc. | Results Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials q4web.com ↗
The randomized 1:1:1:1:1, observer-blind, active-controlled study of mRNA-1468 elicited strong antigen-specific T cell responses at one month after the second dose and was generally well tolerated. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-27 | ModernaTX, Inc. | Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials q4web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1468 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05701800 ↗ |
| Modality | Vaccine | “mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ)” NCT05701800 ↗ |
| Route | Intramuscular | “Participants will receive mRNA-1468 by IM injection on Day 1 and Day 57 in Part 1.” NCT05701800 ↗ |